Genetically modified Plasmodium parasites as a protective experimental malaria vaccine

Area of Science:

• Malariology
• Vaccinology
• Parasitology

Background:

• Malaria is a significant global health threat transmitted by Plasmodium parasites.
• The pre-erythrocytic stage, specifically liver-stage parasites, is a key target for malaria vaccines.
• Eliminating liver-stage parasites can prevent infection and disease.

Purpose of the Study:

• To investigate the role of the UIS3 gene in Plasmodium liver-stage development.
• To evaluate the potential of UIS3-deficient sporozoites as a malaria vaccine candidate.

Main Methods:

• Utilized expression profiling to identify pre-erythrocytic stage genes.
• Employed reverse genetics to create and test uis3-deficient Plasmodium sporozoites.
• Assessed vaccine efficacy in a rodent malaria model.

Main Results:

• UIS3 (upregulated in infective sporozoites gene 3) is essential for early liver-stage development.
• uis3-deficient sporozoites successfully infect hepatocytes but fail to establish blood-stage infections.
• Immunization with uis3-deficient sporozoites provided complete, sustained, and stage-specific protection against malaria challenge in rodents.

Conclusions:

• UIS3 is a critical factor for Plasmodium parasite development in the liver.
• Genetically attenuated whole-organism malaria vaccines targeting liver stages are feasible.
• UIS3-deficient sporozoites represent a promising candidate for a safe and effective malaria vaccine.